1Q22 Business Results
Pipeline
✓ Limited competition with post-CT-P16 portfolio
✓ Modest top-line growth is expected to continue by launching at least 1 biological product every year
Reference
Product Name
Manufacturer
Drug
Global
Market size
($bn)
US
EU
RemsimaⓇ SC
Celltrion
52.9
In Phase 3 Clinical Trials
(Mar.2019~)
All Indications Approved
(Jul.2020, Pediatric usage non-included)
Received European
Commission Approval
(Feb.2021)
Application Submitted
(Oct.2021)
In Global Phase 3 Clinical Trials
(Nov.2020~)
YuflymaⓇ
(CT-P17)
HumiraⓇ
(Adalimumab)
Application Submitted
AbbVie
34.6
(Nov.2020)
CT-P16
AvastinⓇ
(Bevacizumab)
Application Submitted
Roche
6.1
(Sep.2021)
CT-P42
Eylea®
(Aflibercept)
Bayer &
Regeneron
4.8
CT-P39
XolairⓇ
(Omalizumab)
Genentech
3.7
CT-P43
StelaraⓇ
(Ustekinumab)
Johnson & Johnson
14.1
CT-P41
ProliaⓇ
(Denosumab)
Amgen
5.8
Note: global market size is as of 2021
Source: IQVIA
In Global Phase 3 Clinical Trials
(Jul.2020~)
In Global Phase 3 Clinical Trials
(Sep.2020~)
In Global Phase 3 Clinical Trials
(Jan.2021~)
Investor Relations 2022 14View entire presentation